Peripheral T cell lymphomas are a heterogeneous group of post-thymic, mature lymphoid
malignancies, accounting for approximately 10–15% of all non-Hodgkin's lymphomas. A …

Anthracycline‐based chemotherapy remains standard treatment for peripheral T‐cell
lymphoma (PTCL) although its benefits have been questioned. We performed systematic …

Purpose Romidepsin is a structurally unique, potent class 1 selective histone deacetylase
inhibitor. The primary objective of this international, pivotal, single-arm, phase II trial was to …

Purpose Peripheral T-cell lymphoma (PTCL) is a poor prognosis subtype of non-Hodgkin's
lymphoma with no accepted standard of care. This study evaluated the efficacy and …

To evaluate outcome and prognosis of patients with T-cell lymphoma we analyzed 343
patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study …

Abstract The International Peripheral T-cell Lymphoma Project is a collaborative effort to
better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted …

To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively
analyzed 385 cases fulfilling the criteria defined by the World Health Organization …

Purpose Peripheral T-cell lymphomas (PTCLs) are rare malignancies with poor outcome
after conventional chemotherapy. The role of myeloablative therapy and autologous stem …

Purpose Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-
cell tumor in Western countries, no study to date has been based on the application of a …

Background All peripheral T-cell lymphomas (PTCLs) diagnosed at a single institution were
evaluated to determine the unique clinical features and outcome of specific entities and test …